FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next >>
 
TXT Dental Bone Graft Animal Study Guide
03/28/2024
 
 
TXT FDA Approves Akebia Vafseo for Some Anemias
03/28/2024
 
 
TXT Aldeyra Plans for Reproxalap NDA Resubmission
03/28/2024
 
 
TXT 3-year-old Fusion IV FDA-483 Released
03/28/2024
 
 
TXT ASCA Pilot Met, Exceeded Expectations: CDRH
03/28/2024
 
 
TXT Amneal Recalls 4 Lots of Vancomycin
03/28/2024
 
 
TXT FDA OKs Expanded Use for Hepatitis B Drug
03/28/2024
 
 
TXT Medexus’ Hemophilia B Factor Gets Expanded Use
03/28/2024
 
 
TXT 2 REMS Assessment MAPPs
03/27/2024
 
 
TXT FDA ‘Fails to Follow Science’ in Electroshock Case: Attorneys
03/27/2024
 
 
TXT BIO Suggestions for CGT Potency Guidance
03/27/2024
 
 
TXT Catalent Indiana FDA-483
03/27/2024
 
 
TXT Merck BLA for Winrevair Approved
03/27/2024
 
 
TXT Proposed Ban on Certain e-Stimulation Devices
03/27/2024
 
 
TXT Weiner Moves to Foreign Inspections Office
03/27/2024
 
 
TXT Boston Scientific Recalls PolarSheath Steerable
03/27/2024
 
 
TXT FDA Approves Medtronic Evolut FX+
03/27/2024
 
 
TXT Revised BA/BE Sample Handling Guidance
03/26/2024
 
 
TXT Bioresearch Monitoring Issues at New York Site
03/26/2024
 
 
TXT Mesoblast Refiling BLA for Remestemcel-L
03/26/2024
 
 
TXT CGMP Violations at Deqing Jiarou
03/26/2024
 
 
TXT Multiple Violations in ReNovo Inspection
03/26/2024
 
 
TXT Rep. Questions Musk Device Trial OK Before Inspection
03/26/2024
 
 
TXT Antibody Drug Conjugate Guidance Explained
03/26/2024
 
 
TXT High Court Skeptical on Mifepristone Restrictions
03/26/2024
 
 
TXT Clinical Data Interchange Standards Update
03/26/2024
 
 
TXT Quantitative Medicine Center of Excellence Created
03/25/2024
 
 
TXT J&J’s Opsynvi OK’d for Pulmonary Hypertension
03/25/2024
 
 
TXT Regeneron Complete Response on Lymphoma BLA
03/25/2024
 
 
TXT FDA Again Seeks Ban on Shock Devices
03/25/2024
 
 
TXT GAO Report Hits FDA on Investigator Retention
03/25/2024
 
 
TXT Arrow QuickFlash Radial Artery Catheter Recall
03/22/2024
 
 
TXT Italfarmaco Wins Approval for Duchenne Drug
03/22/2024
 
 
TXT FTC Challenges Teva Orange Book Listings
03/22/2024
 
 
TXT FDA Settles Ivermectin Messaging Lawsuit
03/22/2024
 
 
TXT Clarity in RWE Guidance is Welcome: Attorneys
03/22/2024
 
 
TXT Organon Wants Generic Nexplanon Restrictions
03/21/2024
 
 
TXT 4 Observations in Medi-Fare Inspection
03/21/2024
 
 
TXT FDA Grants, Denies Draize Test Petition
03/21/2024
 
 
TXT AdvaMed on Metallic Coatings Characterization
03/21/2024
 
 
TXT Safety Labeling Changes for Fluorouracil Injection
03/21/2024
 
 
TXT Vyaire Recalls AirLife Resuscitators
03/21/2024
 
 
TXT Hearing Challenges FDA Rule on LDTs
03/21/2024
 
 
TXT Phase 3 Keytruda Miss in Lung Cancer
03/21/2024
 
 
TXT Elixir Gets ‘Breakthrough’ for DynamX BTK
03/21/2024
 
 
TXT Panel to Discuss Non-invasive Ocular Pump
03/20/2024
 
 
TXT Key Patient Long Covid Meeting Themes
03/20/2024
 
 
TXT Check Key Info in Informed Consent
03/20/2024
 
 
TXT Non-Interventional Studies Guidance
03/20/2024
 
 
TXT CBER AI/ML Web Page
03/20/2024
 
 
TXT Fujifilm AI Colonoscopy Polyp Detector Cleared
03/20/2024
 
 
TXT FDA OKs Tryvio as Add-on for Hypertension
03/20/2024
 
 
TXT FDA Warning Letters on Chinese Syringes
03/19/2024
 
 
TXT Disease Awareness Ads Can Confuse: FDA Study
03/19/2024
 
 
TXT Digital Health Research Grants Available
03/19/2024
 
 
TXT FDA to Make Compounding ‘Difficulty’ Lists
03/19/2024
 
 
TXT Bipartisan Bill to Shore Up Emergency APIs
03/19/2024
 
 
TXT Renal PK Study Guidance
03/19/2024
 
 
TXT Iclusig Accelerated Approval for Leukemia
03/19/2024
 
 
TXT FDA Accepts BLA Resubmission for Lymphir
03/19/2024
 
 
TXT Senators Want Defense Drug Supply Security Update
03/19/2024
 
 
TXT Changes Proposed to Manufacturing Tech Draft
03/19/2024
 
 
TXT FDA Cites GMPs in Abeona Inspection
03/18/2024
 
 
TXT Guide on Animal Drug Mfg. Batches
03/18/2024
 
 
TXT Biotronik Breakthrough Status for Freesolve Device
03/18/2024
 
 
TXT GSK Reports Favorable Jemperli Phase 3 Data
03/18/2024
 
 
TXT Eugia Inspection Results in 7-Item FDA 483
03/18/2024
 
 
TXT Bayer’s Aliqopa Withdrawn Over Failed Confirmation
03/18/2024
 
 
TXT Orchard’s Leukodystrophy Gene Therapy OK’d
03/18/2024
 
 
TXT Sleepnet Recalls Sleep Apnea Masks
03/18/2024
 
 
TXT CDER Launches Inspections Web Page
03/15/2024
 
 
TXT More Info on Quality Manufacturing Maturity
03/15/2024
 
 
TXT Generic Drug Controlled Correspondence Guidance
03/15/2024
 
 
TXT FDA Paper on AI Targets 4 Focus Areas
03/15/2024
 
 
TXT Device Q-Submission Feedback Draft Guidance
03/15/2024
 
 
TXT FDA Guidance on Device Thermal Effects
03/14/2024
 
 
TXT Updated Draft Q-Submission Guidance
03/14/2024
 
 
TXT Comments on Advanced Mfg. Tech Guide
03/14/2024
 
 
TXT Medos Recalls Cerebase DA Guide Sheath
03/14/2024
 
 
TXT Notice Corrected on Flowtuss NDA Withdrawal
03/14/2024
 
 
TXT ‘Damning Report’ on Alzheimer Drug Tests: Article
03/14/2024
 
 
TXT Cassidy Wants Test Regulation Ideas
03/14/2024
 
 
TXT FDA Approves Madrigal Fatty Liver Drug
03/14/2024
 
 
TXT Post-Approval Safety Data Reporting Guide
03/13/2024
 
 
TXT Advisors to Weigh Imetelstat Benefits, Risks
03/13/2024
 
 
TXT ODAC Looking at Increased Deaths in 2 Drugs
03/13/2024
 
 
TXT Need to Creatively Regulate Software as Device: Atty.
03/13/2024
 
 
TXT FDA Budgets to Expand ‘Foreign Footprint’
03/13/2024
 
 
TXT Petition Seeks More Ozempic, Mounjaro Trials
03/13/2024
 
 
TXT Breakthrough Status for Anxiety Disorder Drug
03/13/2024
 
 
TXT PhRMA Seeks Waivers on Patient Medication Info
03/13/2024
 
 
TXT Ensartinib NDA Accepted for Lung Cancer
03/13/2024
 
 
TXT Drug Supply Small Dispenser Info Collection
03/13/2024
 
 
TXT Help Industry with ‘Bad Labs’: Post
03/12/2024
 
 
TXT QS, MDR Issues Seen in Exactech Inspection
03/12/2024
 
 
TXT Minor Drug Labeling Change Reporting Guide
03/12/2024
 
 
TXT ‘False or Misleading’ Senvelgo Claims: CVM
03/12/2024
 
 
TXT Cybersecurity Guidance Updates Proposed
03/12/2024
 
 
TXT Digital Drug Marketing Workshop Themes
03/12/2024
 
 
TXT Most MDRs Hit Device Function Issues: Study
03/12/2024
 
 
<< Prev  4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving